SENS News and Press, Senseonics Holdings Inc. From 05/12/24

2024-05-12 17:35:55 ET Major earnings expected after the bell on Monday include: Petróleo Brasileiro S.A. - Petrobras ( PBR ) Lithium Americas (Argentina) Corp. ( LAC ) StoneCo Ltd. ( STNE ) Inovio Pharmaceuticals ( INO ) Alcon ( ALC ) ...

2024-05-09 17:06:59 ET More on Senseonics Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript Senseonics slips amid concerns over demand for Eversense Senseonics GAAP EPS of -$0.03 beats by $0.01, revenue of $8M beats by $0.38M Seeking Alpha...

Eversense ® CGM+RPM solution to be powered by Rimidi’s clinical management platform Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) sy...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Globa...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial resu...

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, impla...

SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS PR Newswire Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PA...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense ® Post Approval Study is to b...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare Me...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December ...